Physician profile
Vilate Thur
NPI 1063478436
$1,888.77
in general payments reported to CMS, 2019-2025
33 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $408 · 2022: $476 · 2023: $318 · 2024: $351 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $474.76 | 2021-2025 | |
| Lilly USA, LLC | $346.19 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $135.36 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $109.80 | 2024-2025 | Veozah |
| Novo Nordisk INC | $81.81 | 2021-2024 | Ozempic |
| Sanofi-Aventis U.S. LLC | $79.52 | 2022-2023 | |
| Mannkind Corporation | $55.15 | 2021 | |
| Glaxosmithkline, LLC. | $42.97 | 2021-2023 | Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $41.90 | 2024-2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.92 | 2025 | Caplyta |
| Corium, LLC | $35.93 | 2024 | Azstarys |
| Pfizer INC. | $32.08 | 2021-2025 | |
| Boston Scientific Corporation | $31.47 | 2021 | |
| Merck Sharp & Dohme LLC | $29.74 | 2023-2025 | Vaxneuvance, M-M-R II, Rotateq |
| Biohaven Pharmaceuticals, INC. | $26.50 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26.15 | 2022 | |
| Idorsia Pharmaceuticals US INC | $26.02 | 2022-2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $24.79 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $23.52 | 2022 | |
| Eisai INC. | $23.05 | 2021 | |
| Tris Pharma INC | $21.74 | 2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $21.71 | 2021 | |
| Hologic Sales and Service, LLC | $18.47 | 2023 | Aptima |
| Collegium Pharmaceutical, INC. | $16.77 | 2025 | Jornay Pm |
| Gilead Sciences, INC. | $16.16 | 2025 | |
| Sobi, INC | $15.76 | 2022 | |
| Apria Healthcare LLC | $15.29 | 2021 | |
| Cranial Technologies, INC | $15.25 | 2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $14.45 | 2021 | |
| Seqirus USA INC | $14.06 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.01 | 2022 | |
| Neurelis, INC. | $11.92 | 2022 | |
| Dexcom, INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vilate Thur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.